Abstract 1435P
Background
Esophageal squamous cell carcinoma (ESCC) treatment remains challenging due to its high recurrence rates and discouraging survival outcomes. Astragalus Polysaccharides (PG2, PhytoHealth Corporation, Taiwan, ROC), as a drug therapy for cancer-related fatigue relief, has the ability to modulate macrophage polarization and synergistically anti-cancer effect. PG2 combined with neoadjuvant chemoradiotherapy might be a novel therapeutic strategy in patients with ESCC.
Methods
The prospective, multicenter, open-label, and randomized trial included patients with stage IIb to IIIb resectable locally advanced ESCC who would undergo concurrent chemoradiotherapy (CCRT) followed by surgery. Eligible patients were randomized to receive either CCRT combined with PG2 or CCRT alone. This study aimed to identify differences in survival, objective response rate (ORR), and major pathologic response (MPR) rate between two arms. The Immunomodulatory effects of PG2 were also explored.
Results
Thirty-eight ESCC patients were enrolled. CCRT combined with PG2 resulted in significantly superior overall survival (OS) compared to CCRT alone [HR 0.32; 95% CI, 0.1-0.96; P=0.042]. The ORR in CCRT-PG2 arm was 85.0%, higher than that in CCRT alone arm was 62.5%, and progressive disease made surgery unfeasible for 5% of cases in CCRT-PG2 arm, while 25.0% in CCRT alone arm. Primary tumor MPR rate was achieved by 100.0% in CCRT-PG2 Arm and 80.0% in CCRT alone arm, respectively. CCRT-PG2 arm exhibited a consistent and significant decline in blood regulatory T cell proportions, and the suppressions of the serum levels of proinflammatory cytokines (IL-12, IL-1b, and IL-6), immune- suppressive cytokines (IL-10 and IL-4), and angiogenic growth factors (VEGF and MCP-1) were also observed in CCRT-PG2 arm, with a significant difference compared to the CCRT alone arm. PG2 also conferred an immunomodulatory effect by reducing CCRT-induced polarization of tumor-associated macrophages from M1 to M2.
Conclusions
PG2 combined with preoperative CCRT in advanced esophageal cancer has shown promising improvements in OS and modulation of the immune microenvironment.
Clinical trial identification
NCT03611712 (PH-CP028/PH-CP028-1).
Editorial acknowledgement
Legal entity responsible for the study
MacKay Memorial Hospital, Tri-Service General Hospital, Far-Eastern Memorial Hospital, Taipei Medical University - Shuang-Ho Hospital, PhytoHealth Corporation.
Funding
PhytoHealth Corporation, Taiwan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1919P - Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Presenter: Luigi Cerbone
Session: Poster session 18
1918P - Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience
Presenter: Manal Elgendy
Session: Poster session 18
1917P - Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma
Presenter: Vilde Haakensen
Session: Poster session 18
1916P - Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study
Presenter: LUANA CALABRO
Session: Poster session 18
1915P - Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
Presenter: Matthew Ning
Session: Poster session 18
1914P - Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Presenter: Omar Abdel-Rahman
Session: Poster session 18
1913P - Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance
Presenter: Joyce Chan
Session: Poster session 18
1912P - AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
Presenter: Samaantha Bove
Session: Poster session 18
1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France
Presenter: Laurent Greillier
Session: Poster session 18